Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
166. |
ECCT/24/04/08 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Wilson Muraya Site(s) in Kenya 1. KEMRI Mtwapa Clinical Research Site- Kilifi (Kilifi county) |
View |
167. |
ECCT/24/05/01 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Dr Videlis Nduba Site(s) in Kenya 1. KEMRI Centre for Clinical Respiratory Diseases Research (KEMRI CRDR)-Nairobi (Nairobi City county) |
View |
168. |
ECCT/24/05/02 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Jacqueline Mirera Site(s) in Kenya 1. Clinical Research Health Network (CREA-N), Machakos Level 5 Hospital Site (Machakos county) |
View |
169. |
ECCT/24/05/06 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Lucas Otieno Tina Site(s) in Kenya 1. Victoria Biomedical Research Institute (VIBRI) - Kisumu (Kisumu county) |
View |
170. |
ECCT/24/06/01 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Raymond Scott McClelland Site(s) in Kenya 1. Pwani Research Centre (Mombasa county) |
View |